Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Prospector who wrote (1753)	6/25/1998 10:12:00 AM
From: Profiteer	Read Replies (1) \| Respond to of 5402

Yeah Prospector: Is it true that you and Mr. Forthright turned out to be long lost twins and you found each other on the internet? Probably been together all this time going over each other's childhood photographs! Ha ha

To: Prospector who wrote (1753)	6/25/1998 10:15:00 AM
From: Gwolf	Respond to of 5402

Sweet & lovable you got on the wrong side of the SI administration, I find that hard to believe. TeHee. Gwolf

To: Prospector who wrote (1753)	6/25/1998 11:15:00 AM
From: Hyrulean King	Respond to of 5402

Welcome back Prospector did you stake any new claims on your trip? Glad to have you back!!

To: Prospector who wrote (1753)	6/25/1998 7:51:00 PM
From: chirodoc	Respond to of 5402

186 SURGICAL PATIENTS--NO NEGATIVE REACTIONS!!!! EXCEPT ONE PATIENT--LONG TERM USE Ann Surg 1982 Jan;195(1):60-69 Clinical studies of a perfluorochemical whole blood substitute (Fluosol-DA) Summary of 186 cases. Mitsuno T, Ohyanagi H, Naito R After the experimental and phase one studies of our so-called "artificial blood," Fluosol-DA (20%), an emulsified mixture of perfluorodecalin and perfluorotripropylamine, were successfully completed, phase two and three clinical studies were carried out on 186 patients in Japan. The initial dose was 20 ml/Kg body weight (BW), and additional 10 ml/Kg BW doses were applied as needed. Oxygen-supplying and plasma-extending effects were established. No untoward reaction was observed in any of the 186 cases except in a case that involved long-term repeated administration. Initial studies on FLuosol-DA suggest reasonable safety; however, additional clinical trials appear warranted.